Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
July 1, 2025
- Sanofi Releases Typhim Vi, First Typhoid Vaccine in Japan
July 1, 2025
- Servier Files Tibsovo for Biliary Tract Cancer in Japan
July 1, 2025
- ASKA Rolls Out Contraceptive Pill Slinda in Japan
July 1, 2025
- 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
- J-TEC Targets 1,000 Knee OA Cases Per Year for JACC: CEO
June 30, 2025
- Rakuten, Taiwan’s Orient EuroPharma Ink Photoimmunotherapy Deal
June 30, 2025
- Asahi Kasei Kicks Off Japan PIII for Recomodulin for CIPN
June 30, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Fuji Pharma Filed for OTC Approval of Emergency Contraceptive Last October
June 27, 2025
- Chugai Files Alecensa for ALK-Positive Solid Tumors in Japan
June 27, 2025
- Kyowa Kirin Wins Japan Nod for Lumicef Pen Injector
June 27, 2025
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- Japan Approves Crysvita Prefilled Syringe: Kyowa Kirin
June 26, 2025
- SanBio Pushes Back Shipment Approval Timeline for Cell Therapy Akuugo
June 26, 2025
- Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
- Japan Pharma Market to Reach 12.28 Trillion Yen by FY2029: IQVIA
June 25, 2025
- Novartis Taps Cancer Institute Hospital as Priority Trial Site in Japan
June 25, 2025
- FDA Approves Daiichi’s Datroway for EGFR Lung Cancer
June 25, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…